United Kingdom
The information displayed in this site is for products marketed in UK. Please select a product from the following list.
Derma Range
Synalar Cream
Synalar Cream
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0001 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Synalar Gel
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0004 from the list for product information of our laboratory. See MHRA website. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Synalar Ointment 0.025% W/W
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0005 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Synalar Ointment 1 in 4 Dilution
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0006 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Metosyn FAPG Cream
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0014 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Metosyn Ointment
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0015 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Crystacide Cream 1%
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0011 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Hospital Products
Anidulafungin 100 mg
Product information
Powder for concentrate for solution for infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0038 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Bivalirudin 250mg
Product information
Powder for concentrate for solution for injection or infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0035 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Cefotaxime 1g Powder for Solution for Injection or Infusion
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 44095/0030 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Cefotaxime 2g Powder for Solution for Injection or Infusion
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 44095/0031 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Ceftriaxone 1g Powder for Solution for Injection or Infusion
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 44095/0021 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Ceftriaxone 2g Powder for Solution for Injection or Infusion
Product information
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 44095/0034 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Cefuroxime 1.5g
Product information
Powder for Solution for Injection or Infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0033 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Cefuroxime 750mg
Product information
Powder for Solution for Injection.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0032 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Co-amoxiclav 1000 mg/200 mg
Product information
Powder for solution for injection/infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 25174/0034 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Daptomycin 350 mg
Product information
Powder for solution for injection or infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0020 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Daptomycin 500 mg
Product information
Powder for solution for injection or infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0029 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Ganciclovir 500 mg
Product information
Powder for concentrate for solution for infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0036 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Piperacillin/Tazobactam 2 g/0.25 g
Product information
Powder for solution for infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0024 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Piperacillin/Tazobactam 4 g/0.5 g
Product information
Powder for solution for infusion.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0025 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Sodium Oxybate 500 mg/ml
Product information
Oral solution.
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL44095/0017 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Micafungin 50 mg
Product information
Powder for concentrate for solution for infusion .
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 48785/005 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Micafungin 100 mg
Product information
Powder for concentrate for solution for infusion .
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 48785/006 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |
Sugammadex 100 mg/mL
Product information
Solution for injection
You will be redirected to the MHRA (Medicines & Healthcare products Regulatory Agency) site information regarding product information on SPCs (Summary of Product Characteristics) for healthcare professionals or PILs (Patient Information Leaflets). Please read the information displayed and tick the box at the bottom of the page to proceed to view the product information in pdf format. You must select PL 44095/0039 from the list for product information of our laboratory. See MHRA website.
| Medical enquiries: | Please click here to send your enquiry. |
| Report a production issue: | Please click here to send your enquiry. |
| Report an adverse event: | Please click here to send your enquiry. |
| Commercial: | Please click here to contact the commercial department. |